Application of long acting pramipexole at advanced stage of Parkinson’s disease. Case reports
- Authors: Fedorova N.V1, Kulua T.K1
-
Affiliations:
- Issue: No 7 (2015)
- Pages: 91-95
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287915
- ID: 287915
Cite item
Open Access
Access granted
Abstract
This article discusses clinical cases of late stage Parkinson's disease with nocturnal symptoms, fluctuations and drug-induced dyskinesia. The use of long acting pramipexole at a dose of 3 mg once a day resulted in a regression of nocturnal symptoms, improvement of sleep, reduction of the severity of levodopa-induced dyskinesias and motor fluctuations.
Full Text
References
- Folstein M.F., Folstein S.E., McHugh P.R. «Minimental state». A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12(3):189-98.
- Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17(5):427-42.
- Rajput A.H. Levodopa prolongs life expectancy and is non-toxic to substantianigra. Parkinsonizm. Relat. Dis. 2001;8:95-100.
- Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology. 1998;51:25-9.
- Rajput A.H., Fenton M.E., Birdi S., Macaulay R., George D., Rozdilsky B., Ang L.C., Senthilselvan A., Hornykiewicz O. Clinical-patological study of levodopa complications. Mov. Dis. 2002;17:289-96.
- Markham C.H., Diamond S.G. Evidence to support early levodopa therapy in Parkinson's disease. Neurology (Minneap). 1981;31:125-31.
- Chaudhuri K.R. Nocturnal symptom complex in Parkinson's Disease and its management. Neurology. 2003;61:S17-23.
- Chaudhuri K.R., Pal S., Bridgman K., Trenkwalder C. Achieving 24-hour control of Parkinson's disease symptoms; use of objective measures to improve nocturnal disability. Eur. Neurol. 2001;46(Suppl. l):3-10.
- Stocchi F., Brusa L., Vacca L., et al. Sleep disturbances in Parkinson's disease. Eur. J. Neurol. 2000;7(Suppl. 4):21-5.
- Lees A.J., Blackburn N.A., Campbell V.L. The nighttime problems of Parkinson's disease. Clin. Neuropharmacol. 1988;11:512-19.
- Ferreira J.J., Katzenschlager R., Bloem B.R., Bonuccelli U., Burn D., Deuschl G., Dietrichs E., Fabbrini G., Friedman A., Kanovsky P., Kostic V., Nieuwboer A., Odin P., Poewe W., Rascol O., Sampaio C., Schüpbach M., Tolosa E., Trenkwalder C., Schapira A., Berardelli A., Oertel W.H. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur. J. Neurol. 2013;20(1):5-15.
- Gutman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole - Bromocriptine Study Group. Neurology. 1997;49:1060-65.
- Mizuno Y., Yanagisawa N., Kuno S., Yamamoto M., Hasegawa K., Origasa H., Kowa H. Randomised double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's diseas. The Japanese Pramipexole Study Group. Mov. Disord. 2003;18: 1149-56.
- Navan P., Findley L.J., Undy M.B., Pearce R.K., Bain P.G. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide. Eur. J. Neurol. 2005; 12(1):1-8.
- Barone P., Poewe W., Albrecht S., Debieuvre C., Massey D., Rascol O., Tolosa E., Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trail. Lancet Neurol. 2010;9:573-80.
- Grosset D., Antonini A., Caneci M., Pezzoli G., Lees A., Shaw K., Cubo E., Martinez-Martin P., Rascol O., Negre-Pages L., Senard A., Schwarz J., Strecker K., Reichmann H., Storch A., Löhle M., Stocchi F., Grosset K. Adherence to antiparkinson medication in a multicenter European study. Mov. Disord. 2009;24:826-32.
- Schapira A.H., Barone P., Hauser R.A., et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease. Mov. Disord. 2009;24 (Suppl. 1):277-78.
- Fahn S., Elton R.L., and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C.D., Calne D., Goldstein M., eds. Recent developments in Parkinson's disease. Florham Park, N.J.: Macmillan Healthcare Information, 1987;153-63.
- Hauser R., Schapira A., Barone P., Mizuno Y., Rascol O., Busse M., Debieuvre C., Fraessdorf M., Poewe W. Lonl-term safety and sustained efficacy of extended-release pramipexole. Parkinson's didease. European J. of neurology. 2014;21:736-43.
Supplementary files
